<DOC>
	<DOCNO>NCT00632931</DOCNO>
	<brief_summary>A 2-period , crossover study assess effect MK0683 ( vorinostat ) QTc interval patient relapse refractory advanced cancer .</brief_summary>
	<brief_title>A Crossover Study Assess Effects Vorinostat ( MK0683 , SAHA ) Patients With Advanced Cancer ( 0683-070 ) ( COMPLETED )</brief_title>
	<detailed_description>Merck Duration Treatment : vorinostat ; treatment continue disease progression intolerable toxicity reach</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patient histologicallyconfirmed metastatic locally advanced solid tumor fail respond standard therapy , progress despite standard therapy standard therapy exist Patient life expectancy great 3 month Patient able swallow capsule Patient chemotherapy , radiotherapy biological therapy 2 week prior take study drug Patient currently participate participate study investigational compound device within 30 day sign informed consent Patient active CNS metastasis and/or carcinomatous meningitis Patient primary central nervous system tumor Patient history drug alcohol abuse Patient Hepatitis B C Patient HIV positive Patient active infection receive intravenous antibiotic , antiviral antifungal agent 2 week take study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>